Albendazole is a broad-spectrum benzimidazole anthelmintic agent widely used in the treatment of parasitic worm infections. First discovered in the 1970s, it has become a cornerstone of mass drug administration programs for soil-transmitted helminths and is also employed in the management of systemic cestode and trematode infections. This report provides a concise yet detailed examination of its pharmacology, clinical applications, safety profile, and public health significance.

Chemical and Pharmacological Properties

Albendazole is a synthetic derivative of benzimidazole carbamate. It is poorly soluble in water, which limits oral bioavailability; however, when co-administered with a fatty meal, absorption is significantly enhanced. The drug is rapidly metabolized in the liver to its primary active metabolite, albendazole sulfoxide, which is responsible for most of the therapeutic activity. Albendazole sulfoxide has a half-life of approximately 8–12 hours and is excreted primarily in urine. The drug acts by binding to β-tubulin of parasitic cells, inhibiting microtubule polymerization. This disrupts glucose uptake, leading to energy depletion and eventual death of the parasite. It is active against a wide range of nematodes, cestodes, and some trematodes.

Pharmacokinetics and Dosing

Oral albendazole is variably absorbed; bioavailability is about 20% when taken with a high-fat meal. Peak plasma concentrations of the sulfoxide metabolite occur within 2–4 hours. The drug is highly protein bound (>70%) and distributed widely, including into cerebrospinal fluid and hydatid cysts. Dosing regimens vary by indication. For most soil-transmitted helminthiases (e.g., ascariasis, trichuriasis, hookworm), a single 400 mg dose (for adults and children over 2 years) is given, often repeated for 3 days in strongyloidiasis. For neurocysticercosis and hydatid disease, longer courses (Viagra con Dapoxetine: Revisione Clinica di Efficacia e Sicurezza.g., 400 mg twice daily for 8–30 days) are used, sometimes with corticosteroids to reduce inflammation. Pediatric doses are typically calculated based on body weight (10–15 mg/kg/day).

Clinical Indications

1. Soil-Transmitted Helminths (STH): Albendazole is highly effective against Ascaris lumbricoides (cure rates >95%) and hookworm (Ancylostoma duodenale, Necator americanus) but less so against Trichuris trichiura, where a 3-day regimen or combination with ivermectin is preferred. It is a key component of preventive chemotherapy campaigns in endemic regions.
2. Cestode Infections: It is the drug of choice for neurocysticercosis (caused by Taenia solium larvae), often combined with surgery or corticosteroids. For hydatid disease (Echinococcus granulosus), it is used as first-line therapy, though cure rates vary and prolonged treatment may be required.
3. Trematode Infections: Albendazole has activity against Opisthorchis viverrini and Clonorchis sinensis, but praziquantel is generally preferred.
4. Other Uses: It is used for cutaneous larva migrans, filariasis (in combination with other agents), and some protozoal infections like giardiasis (though less effective than tinidazole).
5. Veterinary Medicine: Widely used in livestock for gastrointestinal roundworms, lungworms, and tapeworms.

Adverse Effects and Safety

Albendazole is generally well tolerated. Common side effects include mild gastrointestinal disturbances (nausea, abdominal pain, diarrhea) and headache. Rare but serious adverse effects include bone marrow suppression (neutropenia, thrombocytopenia), liver enzyme elevation, and alopecia. Hepatotoxicity is more common with prolonged high-dose therapy; monitoring of liver function is recommended during extended courses. The drug is classified as pregnancy category C (in some sources D) due to teratogenicity observed in animal studies; it is contraindicated during pregnancy, especially in the first trimester. Women of childbearing age are advised to use contraception during treatment. Children under 2 years may be treated if the benefit outweighs risk, though data are limited.

Contraindications and Interactions

Absolute contraindications include known hypersensitivity and pregnancy. Caution is needed in patients with liver disease, cirrhosis, or bone marrow suppression. Albendazole is metabolized by CYP3A4; inhibitors like cimetidine can increase its levels, while inducers like phenytoin may reduce efficacy. The drug may also increase the effects of warfarin.

Resistance and Challenges

Resistance to albendazole has been documented in veterinary settings and is emerging in human parasites, particularly in Trichuris trichiura and hookworm. Mechanisms involve mutations in β-tubulin genes and enhanced drug efflux. In response, combination therapy (e.g., albendazole plus ivermectin) is increasingly recommended. Additionally, mass drug administration programs face challenges of coverage, compliance, and reinfection in endemic areas.

Public Health Significance

Soil-transmitted helminthiases affect over 1.5 billion people globally, mostly in sub-Saharan Africa, Asia, and the Americas. Albendazole, often donated by pharmaceutical companies, is central to World Health Organization strategies for morbidity control. It is also used in lymphatic filariasis elimination as part of triple therapy. The drug’s low cost, single-dose efficacy, and safety profile make it ideal for large-scale use.

Conclusion

Albendazole remains an essential anthelmintic in both human and veterinary medicine. Its broad spectrum, oral availability, and generally favorable safety profile have made it a mainstay for treating intestinal worms, cysticercosis, and hydatid disease. Ongoing surveillance for resistance, optimization of dosing schedules, and efforts to improve access in resource-limited settings are critical to maintaining its utility. As newer agents and combination therapies emerge, albendazole will likely continue to be a vital weapon against parasitic infections for the foreseeable future.